IL155263A0 - Pharmaceutical solutions of modafinil compounds - Google Patents

Pharmaceutical solutions of modafinil compounds

Info

Publication number
IL155263A0
IL155263A0 IL15526301A IL15526301A IL155263A0 IL 155263 A0 IL155263 A0 IL 155263A0 IL 15526301 A IL15526301 A IL 15526301A IL 15526301 A IL15526301 A IL 15526301A IL 155263 A0 IL155263 A0 IL 155263A0
Authority
IL
Israel
Prior art keywords
modafinil compounds
pharmaceutical solutions
modafinil
pharmaceutical
compounds
Prior art date
Application number
IL15526301A
Other languages
English (en)
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of IL155263A0 publication Critical patent/IL155263A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15526301A 2000-10-11 2001-10-11 Pharmaceutical solutions of modafinil compounds IL155263A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23948800P 2000-10-11 2000-10-11
US09/974,473 US6489363B2 (en) 2000-10-11 2001-10-10 Pharmaceutical solutions of modafinil compounds
PCT/US2001/031685 WO2002030413A1 (en) 2000-10-11 2001-10-11 Pharmaceutical solutions of modafinil compounds

Publications (1)

Publication Number Publication Date
IL155263A0 true IL155263A0 (en) 2003-11-23

Family

ID=26932612

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15526301A IL155263A0 (en) 2000-10-11 2001-10-11 Pharmaceutical solutions of modafinil compounds
IL155263A IL155263A (en) 2000-10-11 2003-04-06 Pharmaceutical solutions of modafinil compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155263A IL155263A (en) 2000-10-11 2003-04-06 Pharmaceutical solutions of modafinil compounds

Country Status (22)

Country Link
US (1) US6489363B2 (xx)
EP (1) EP1324755B1 (xx)
JP (1) JP2004510816A (xx)
KR (1) KR100846914B1 (xx)
CN (1) CN100518726C (xx)
AT (1) ATE478662T1 (xx)
AU (2) AU2001296785B2 (xx)
BG (1) BG66221B1 (xx)
BR (1) BR0114813A (xx)
CA (1) CA2425218C (xx)
CZ (1) CZ2003966A3 (xx)
DE (1) DE60142913D1 (xx)
EA (1) EA005572B1 (xx)
HK (1) HK1057336A1 (xx)
HU (1) HU229424B1 (xx)
IL (2) IL155263A0 (xx)
MX (1) MXPA03003150A (xx)
NO (1) NO333096B1 (xx)
NZ (1) NZ525166A (xx)
PL (1) PL214879B1 (xx)
SK (1) SK287436B6 (xx)
WO (1) WO2002030413A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215226B1 (pl) * 2000-10-11 2013-11-29 Cephalon Kompozycja farmaceutyczna zawierajaca zwiazek modafinilu, sposób jej wytwarzania oraz jej zastosowanie
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US20070066996A1 (en) * 2003-03-17 2007-03-22 Katzman Daniel E Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
AR046410A1 (es) * 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
BRPI0500520A (pt) * 2005-02-16 2006-09-26 Henry Jun Suzuki uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas
EP1909573A4 (en) * 2005-07-21 2010-09-22 Neurohealing Pharmaceuticals I SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE
CA2660565C (en) * 2006-08-14 2012-10-09 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
CA2629979A1 (en) * 2008-04-25 2009-10-25 Pharmascience Inc. Novel resveratrol compositions
FR2987265B1 (fr) 2012-02-28 2014-02-28 Debregeas Et Associes Pharma Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application
FR2987266B1 (fr) 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
EA028481B1 (ru) * 2012-10-18 2017-11-30 Эббви Инк. Препараты производных пиримидиндиона
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function

Also Published As

Publication number Publication date
HK1057336A1 (en) 2004-04-02
WO2002030413A1 (en) 2002-04-18
HUP0302478A3 (en) 2005-05-30
BG107720A (bg) 2004-01-30
PL361134A1 (en) 2004-09-20
KR100846914B1 (ko) 2008-07-17
EA005572B1 (ru) 2005-04-28
NO20031648L (no) 2003-06-04
MXPA03003150A (es) 2003-07-14
CN100518726C (zh) 2009-07-29
DE60142913D1 (de) 2010-10-07
HU229424B1 (hu) 2013-12-30
EA200300450A1 (ru) 2003-08-28
CN1468096A (zh) 2004-01-14
CZ2003966A3 (cs) 2003-09-17
SK287436B6 (sk) 2010-09-07
US6489363B2 (en) 2002-12-03
KR20030055279A (ko) 2003-07-02
ATE478662T1 (de) 2010-09-15
BG66221B1 (bg) 2012-06-29
PL214879B1 (pl) 2013-09-30
EP1324755B1 (en) 2010-08-25
NO20031648D0 (no) 2003-04-10
NZ525166A (en) 2006-10-27
CA2425218A1 (en) 2002-04-18
BR0114813A (pt) 2005-01-25
US20020099097A1 (en) 2002-07-25
NO333096B1 (no) 2013-03-04
CA2425218C (en) 2010-10-05
HUP0302478A2 (hu) 2003-11-28
AU9678501A (en) 2002-04-22
SK4402003A3 (en) 2003-09-11
JP2004510816A (ja) 2004-04-08
IL155263A (en) 2007-07-24
AU2001296785B2 (en) 2006-03-16
EP1324755A1 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
HK1057336A1 (en) Pharmaceutical solutions of modafinil compounds
HK1079446A1 (en) Pharmeceutical solid dispersions of modafinil compounds
HK1080763A1 (en) Broad spectrum anti-viral compounds, pharmaceutical formulations and the use thereof
SE0100901D0 (sv) New composition
AP2003002755A0 (en) Guanidinobenzamides as mc4-r agonists
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
MXPA03007140A (es) Derivados de carbolina.
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
ATE231872T1 (de) Thiazolopyrimidinderivate
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
WO2003066597A3 (en) Guanidino compounds
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
DK1330244T3 (da) Præparater der omfatter modafinilforbindelser
NO20051261L (no) Morfin-6-glukuronidsalt
AU2002368133A1 (en) 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
SE0001916D0 (sv) Novel formulation
EP1436279A4 (en) CHEMICAL COMPOUNDS
PL355113A1 (en) Novel fusidic acid derivatives
ATE382363T1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
WO2000050023A3 (en) Use of tamoxifen and related compounds as CLC3 blockers in the treatment of vascular diseases
EP1417968A3 (en) Antitumour compositions containing propolis and resveratrol
AU2002333843A1 (en) Substituted n-(1,4,5,6-tetrahydrocyclopentapyrazol-3-yl) derivatives and the use of the same for the treatment of cancer

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)
FF Patent granted
KB Patent renewed
NP Permission for amending the patent specification granted (section 66, patents law 1967)